The stock of Pulse Biosciences Inc (PLSE) has seen a 2.75% increase in the past week, with a -13.22% drop in the past month, and a -8.55% decrease in the past quarter. The volatility ratio for the week is 3.76%, and the volatility levels for the past 30 days are at 4.91% for PLSE. The simple moving average for the past 20 days is -2.60% for PLSE’s stock, with a -13.08% simple moving average for the past 200 days.
Is It Worth Investing in Pulse Biosciences Inc (NASDAQ: PLSE) Right Now?
Moreover, the 36-month beta value for PLSE is 1.61. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy”, 0 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for PLSE is 12.60M and currently, short sellers hold a 19.46% of that float. On July 04, 2025, PLSE’s average trading volume was 176.61K shares.
PLSE stock’s latest price update
Pulse Biosciences Inc (NASDAQ: PLSE)’s stock price has plunge by -0.13%relation to previous closing price of $15.32. Nevertheless, the company has seen a 2.75% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-05-23 that HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity inducement awards outside of the Company’s 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and.
Analysts’ Opinion of PLSE
Many brokerage firms have already submitted their reports for PLSE stocks, with Stephens repeating the rating for PLSE by listing it as a “Overweight”. The predicted price for PLSE in the upcoming period, according to Stephens is $28 based on the research report published on July 27, 2021 of the previous year 2021.
Maxim Group, on the other hand, stated in their research note that they expect to see PLSE reach a price target of $40. The rating they have provided for PLSE stocks is “Buy” according to the report published on March 11th, 2021.
H.C. Wainwright gave a rating of “Buy” to PLSE, setting the target price at $16 in the report published on May 12th of the previous year.
PLSE Trading at -7.98% from the 50-Day Moving Average
After a stumble in the market that brought PLSE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.80% of loss for the given period.
Volatility was left at 4.91%, however, over the last 30 days, the volatility rate increased by 3.76%, as shares sank -12.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.26% lower at present.
During the last 5 trading sessions, PLSE rose by +2.75%, which changed the moving average for the period of 200-days by -17.34% in comparison to the 20-day moving average, which settled at $15.71. In addition, Pulse Biosciences Inc saw 41.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PLSE starting from UECKER DARRIN, who sold 15,000 shares at the price of $16.40 back on Jun 12 ’25. After this action, UECKER DARRIN now owns 137,872 shares of Pulse Biosciences Inc, valued at $246,000 using the latest closing price.
UECKER DARRIN, the Chief Technology Officer of Pulse Biosciences Inc, sale 15,000 shares at $15.98 during a trade that took place back on Jun 13 ’25, which means that UECKER DARRIN is holding 122,872 shares at $239,700 based on the most recent closing price.
Stock Fundamentals for PLSE
Current profitability levels for the company are sitting at:
- -76.55% for the present operating margin
- -0.64% for the gross margin
The net margin for Pulse Biosciences Inc stands at -72.41%. The total capital return value is set at -0.51%. Equity return is now at value -77.86%, with -66.00% for asset returns.
Based on Pulse Biosciences Inc (PLSE), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -4.67.
Currently, EBITDA for the company is -52.41 million with net debt to EBITDA at 1.76. When we switch over and look at the enterprise to sales, we see a ratio of 1108.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.58.
Conclusion
To wrap up, the performance of Pulse Biosciences Inc (PLSE) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
